HS
OLMA icon

HighVista Strategies’s Olema Pharmaceuticals OLMA Stock Holding History

HighVista Strategies’s Portfolio OLMA Stock Details OLMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2M Buy
160,167
+42,566
+36% +$570K 0.46% 61
2026
Q1 		$1.75M Sell
117,601
-123,888
-51% -$2.76M 0.48% 63
2025
Q4 		$6.04M Sell
241,489
-195,690
-45% -$3.48M 1.55% 18
2025
Q3 		$4.28M Buy
437,179
+158,749
+57% +$953K 1.05% 22
2025
Q2 		$1.19M Buy
278,430
+66,245
+31% +$295K 0.44% 97
2025
Q1 		$798K Hold
212,185
– – 0.31% 117
2024
Q4 		$1.24M Hold
212,185
– – 0.46% 99
2024
Q3 		$2.53M Sell
212,185
-35,695
-14% -$456K 0.87% 33
2024
Q2 		$2.68M Hold
247,880
– – 0.98% 28
2024
Q1 		$2.81M Hold
247,880
– – 1% 29
2023
Q4 		$3.48M Hold
247,880
– – 1.26% 24
2023
Q3 		$3.06M Sell
247,880
-44,396
-15% -$453K 1.42% 17
2023
Q2 		$2.64M Buy
+292,276
New +$1.76M 1.21% 24
2022
Q1 		– Sell
-50,942
Closed -$477K – 94
2021
Q4 		$477K Buy
50,942
+29,943
+143% +$620K 0.38% 65
2021
Q3 		$579K Sell
20,999
-8,123
-28% -$219K 0.38% 69
2021
Q2 		$815K Buy
29,122
+14,667
+101% +$417K 0.58% 40
2021
Q1 		$480K Buy
+14,455
New +$619K 0.36% 72

Other funds holding OLMA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

HighVista Strategies's OLMA Position: Q2 2026 in Review

HighVista Strategies increased its Olema Pharmaceuticals (OLMA) stake by 36% in Q2 2026, buying an estimated $570K and bringing the position to 160,167 shares worth $2M. The position accounts for 0.46% of the portfolio, ranked #61.

HighVista Strategies first reported a position in OLMA in Q1 2021 and has held it in 17 quarters since. The position peaked at $6.04M in Q4 2025. 185 funds tracked by Wall St. Rank hold OLMA as of Q2 2026.

  • HighVista Strategies held 160,167 shares of Olema Pharmaceuticals worth $2M as of Q2 2026.
  • HighVista Strategies bought 42,566 Olema Pharmaceuticals shares in Q2 2026, an estimated $570K.
  • Olema Pharmaceuticals made up 0.46% of HighVista Strategies's portfolio in Q2 2026, its #61 holding.
  • HighVista Strategies first reported a position in Olema Pharmaceuticals in Q1 2021 and has held it in 17 quarters since.
  • HighVista Strategies's Olema Pharmaceuticals position peaked at $6.04M in Q4 2025.
  • 185 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q2 2026.

Based on HighVista Strategies's 13F filing for Q2 2026, filed 14 Aug 2026.